ESMO/LinkedIn
Oct 10, 2024, 14:20
Promising antitumour activity of new treatment modalities advanced solid tumours – ESMO
“Unleashing the power of immunotherapy in oncology is still challenging. While it improves outcomes for many patients with cancer, not all benefit from it, and response rates vary across different tumour types.
Data from early-phase Clinical Trials presented at ESMO24 show promising antitumour activity of new treatment modalities that could further strengthen today’s immuno-oncology toolbox, especially in advanced solid tumours.
Read the On Target column by Elena Garralda Cabanas on ESMO Daily Reporter to learn more about this topic.”
More posts featuring ESMO on oncodaily.com
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08
Nov 13, 2024, 16:02
Nov 13, 2024, 15:56
Nov 13, 2024, 15:46
Nov 13, 2024, 15:32